“…Also, ESA recipients in the current study were exposed to fewer transfusions, which possibly impacted their neurodevelopmental outcomes. 18,19 In animal models, ESAs are protective in the developing brain, suggesting the possibility that they might be of benefit to very premature infants who are at risk for intraventricular hemorrhage, hypoxicischemic injury, and developmental delay. The neuroprotective mechanisms of ESAs include decreased neuronal apoptosis, decreased inflammation, promotion of oligodendrocyte differentiation and maturation, and improved white matter survival.…”